PULMATRIX, INC. Line of Credit, Current
PULMATRIX, INC. (PULM) had Line of Credit, Current of $51.00 thousand as of 2020-12-31, per its 10-K filed 2021-03-23.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Debt, Current › Long-Term Debt, Current Maturities
us-gaap:LinesOfCreditCurrent · last filed 2021-03-23
- 2020-12-31: Line of Credit, Current $51.00K.
| Period end | Line of Credit, Current |
|---|---|
| 2020-12-31 | $51.00K 10-K · filed 2021-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |